APEX1 and neuroblastoma: Subjects carrying 1-3 combined protective genotypes of APEX1 have a lower risk of neuroblastoma when compared with those without a protective genotype, though not statistically significant (adjusted OR = 0.81, 95%CI = 0.64‐1.01, P = 0.064) (Table 1).